NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,450 | -61.1% | 3,000 | 0.0% | 0.00% | -63.6% |
| Q2 2023 | $124,500 | -5.9% | 3,000 | +36.4% | 0.01% | -8.3% |
| Q1 2023 | $132,308 | -18.4% | 2,200 | -0.5% | 0.01% | -25.0% |
| Q4 2022 | $162,104 | +17.5% | 2,210 | +22.1% | 0.02% | +14.3% |
| Q3 2022 | $138,000 | +9.5% | 1,810 | 0.0% | 0.01% | +16.7% |
| Q2 2022 | $126,000 | -15.4% | 1,810 | +0.6% | 0.01% | +33.3% |
| Q1 2022 | $149,000 | +9.6% | 1,800 | -0.3% | 0.01% | +12.5% |
| Q4 2021 | $136,000 | -11.1% | 1,805 | +36.6% | 0.01% | -27.3% |
| Q3 2021 | $153,000 | -47.8% | 1,321 | 0.0% | 0.01% | -42.1% |
| Q2 2021 | $293,000 | +67.4% | 1,321 | 0.0% | 0.02% | +58.3% |
| Q1 2021 | $175,000 | -23.6% | 1,321 | 0.0% | 0.01% | -33.3% |
| Q4 2020 | $229,000 | +56.8% | 1,321 | +0.5% | 0.02% | +38.5% |
| Q3 2020 | $146,000 | +87.2% | 1,315 | 0.0% | 0.01% | +116.7% |
| Q2 2020 | $78,000 | +1850.0% | 1,315 | +1923.1% | 0.01% | – |
| Q1 2020 | $4,000 | -20.0% | 65 | 0.0% | 0.00% | – |
| Q4 2019 | $5,000 | – | 65 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |